Fig. 4From: Brain pharmacokinetics of mono- and bispecific amyloid-β antibodies in wild-type and Alzheimer’s disease mice measured by high cut-off microdialysisIba1 and GFAP staining of the intact hippocampus contralateral to the probe and in the close proximity to the microdialysis probe in the hippocampus in wild-type (Wt) (a) and AppNL−G−F mice (b) that were perfused 24 h after an intravenous injection of [125I]I-mAb3D6 or [125I]I-mAb3D6-scFv8D3Back to article page